MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

NU223612

CAS No. : 2759420-43-2

MCE 站：NU223612

产品活性：NU223612 是一种有效的 PROTAC (PROTACs)，可降解吲哚胺 2,3-双加氧酶 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO))，K_d 为 640 nM。NU223612 通过 CRBN 介导的蛋白酶体降解有效降解 IDO1 蛋白。NU223612 以 290 nM 的亲和力与 CRBN 结合。NU223612 可以穿过血脑屏障 (BBB)。

研究领域：PROTAC  |  Metabolic Enzyme/Protease

作用靶点：PROTACs  |  Indoleamine 2,3-Dioxygenase (IDO)

In Vitro: NU223612 (0.1-10 μM; 24 h) decreases IDO1 protein levels dose-dependently.
A DC₅₀ (the concentration of the NU223612 at which 50% of the IDO1 protein is degraded) of 0.3290 μM ａnd 0.5438 μM in U87 ａnd GBM43 cells is determined, respectively.
NU223612 degrades IDO1 protein in multiple cell types, such as CD18 ａnd PANC-1 human pancreatic cancer cells, OVCAR5 ａnd SKOV3 human ovarian cancer cells, PC3 human prostate cancer cells, ａnd the syngeneic GL261 mouse IDO1 cDNA-expressing (IDO1-O/E) glioma cell line.
NU223612 equally degrades IDO1 protein levels in both the cytoplasmic ａnd nuclear intracellular compartments in human GBM cells. NU223612 is able to penetrate subcellular compartments.
NU223612 dose-dependently inhibits IDO1 enzyme activity resulting in decreased Kyn levels in cultured IFNγ-stimulated GBM cells. NU223612 inhibits both IDO1-mediated tryptophan metabolism as well as IDO1 non-enzyme-mediated NF-κB p65 transcription factor DNA binding activity.

In Vivo: NU223612 (25 mg/kg; i.p.; once) decreases IDO1 protein in C57BL/6 with mIDO1 cDNA-expressing GL261 cells.
NU223612 (25 mg/kg; i.p.; 5 days/week; for 3 weeks) leads to an increase in median overall survival as well as longer-term survival for up to 45 days post-tumor cell injection.
Mass spectrometry analysis of NU223612 (25 mg/kg; i.p.; once) shows a C_max of 2 μM ａnd a half-life of 8.3 h in brain tissue. In plasma, C_max is 365 μM ａnd the half-life is 2.5 h. The binding of NU223612 to mouse brain homogenate using a 6 h equilibrium dialysis shows NU223612 to be 99.8% bound.
Half-life, AUC, andC_maxofNU223612in serum ａnd brain samples.

相关产品：LC-2  |  ACBI2  |  BSJ-04-132  |  IDO1/2-IN-1 hydrochloride  |  PROTAC VEGFR-2 degrader-1  |  SR-1114  |  PROTAC CRABP-II Degrader-3  |  PROTAC Sirt2 Degrader-1  |  CRBN-6-5-5-VHL  |  PROTAC BRD2/BRD4 degrader-1  |  BSJ-03-204  |  JPS016  |  Coptisine chloride  |  KB02-JQ1  |  TD-802  |  BSJ-03-123  |  PROTAC RIPK degrader-6  |  Indoximod  |  VZ185  |  PROTAC BRD9 Degrader-4  |  MS5033  |  PZ703b TFA  |  PROTAC FKBP Degrader-3  |  IDO1-IN-20  |  MS9449  |  SB1-G-187  |  PROTAC CDK2/9 Degrader-1  |  MD-224  |  di-Ellipticine-RIBOTAC  |  ZC0101

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   40,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。